25351-24-0
Chemical Structure
Gentisuric acid
- CAS No.: 25351-24-0
- Formula:C9H9NO5
- Molecular Weight:211.17
IUPAC Name: 1-(4-chlorophenyl)-1H-pyrazole
InChIKey: FBFATOOJCPDQOZ-UHFFFAOYSA-N
SMILES: OC1=CC(C(NCC(O)=O)=O)=C(O)C=C1
Biological Activity: Gentisuric Acid is a metabolite of Aspirin (HY-14654). Gentisuric Acid activates GPR35. Gentisuric Acid inhibits HIF-1α and HIF-2α. Gentisuric Acid inhibits Mitomycin C (HY-13316)-induced genotoxicity and twin spots (mitotic recombination), reduces spot frequency without reducing survival, and modulates replication or repair of Mitomycin C-damaged DNA. Gentisuric Acid can be used in research on VHL-deficient renal cell carcinoma and Drosophila melanogaster infection[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Gentisuric acid | 99.65% | Gentisuric Acid is a metabolite of Aspirin (HY-14654). Gentisuric Acid activates GPR35. Gentisuric Acid inhibits HIF-1α and HIF-2α. Gentisuric Acid inhibits Mitomycin C (HY-13316)-induced genotoxicity and twin spots (mitotic recombination), reduces spot frequency without reducing survival, and modulates replication or repair of Mitomycin C-damaged DNA. Gentisuric Acid can be used in research on VHL-deficient renal cell carcinoma and Drosophila melanogaster infection. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Gentisuric acid (Standard) | ≥98% | Gentisuric acid (Standard) is the analytical standard of Gentisuric acid (HY-W338852). This product is intended for research and analytical applications. Gentisuric Acid is a metabolite of Aspirin (HY-14654). Gentisuric Acid activates GPR35. Gentisuric Acid inhibits HIF-1α and HIF-2α. Gentisuric Acid inhibits Mitomycin C (HY-13316)-induced genotoxicity and twin spots (mitotic recombination), reduces spot frequency without reducing survival, and modulates replication or repair of Mitomycin C-damaged DNA. Gentisuric Acid can be used in research on VHL-deficient renal cell carcinoma and Drosophila melanogaster infection. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Deng H, et al. Aspirin metabolites are GPR35 agonists. Naunyn-Schmiedeberg's archives of pharmacology. 2012 Jul;385(7):729-37. [Content Brief]
- [2]. Niikawa M, et al. Effect of cotreatment of aspirin metabolites on mitomycin C-induced genotoxicity using the somatic mutation and recombination test in Drosophila melanogaster. Drug and chemical toxicology. 2006 Jan 1;29(4):379-96. [Content Brief]
- [3]. Yeoh KK. Studies on the inhibition of human hypoxia inducible factor (HIF) hydroxylases (Doctoral dissertation, et al.
- [4]. Niikawa M, et al. Suppressive effect of post- or pre-treatment of aspirin metabolite on mitomycin C-induced genotoxicity using the somatic mutation and recombination test in Drosophila melanogaster. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2007;61(2-3):113-9. [Content Brief]
